Why Humana Stock Fell 10.9% This Week
Shares of (NYSE: HUM) are down 11.8% so far this week as of Thursday's close, according to data provided by S&P Global Market Intelligence, after the U.S. Centers for Medicare and Medicaid Services (CMS) finalized an "underwhelming" payment rate increase for patients with Medicare Advantage plans in 2025.
In a press release early Monday, the CMS announced its final decision for a 3.7% payment rate increase from the government to Medicare Advantage (MA) plans. While this might sound like a favorable announcement on the surface -- noting that the payments from the government to MA plans should increase by around $16 billion next year -- that 3.7% increase is a risk-adjusted rate accounting for the underlying health of covered enrollees. According to industry analysts who have closely followed the decision, "core" MA payment rates will actually decline by around 0.16% in 2025, after accounting for a combination of expected higher utilization and rising costs of medical care.
That's bad news for companies like Humana that have an outsized reliance on Medicare Advantage membership and cost trends. Even as Humana's consolidated revenue last quarter grew nearly 18% year over year to $26.46 billion, that translated to an adjusted (non-GAAP) net loss of $0.11 per share, down from net income of $1.97 per share in the same year-ago period. That bottom-line loss primarily reflected higher-than-expected inpatient utilization during the quarter from Medicare Advantage patients.
Source Fool.com
Humana Inc. Aktie
Die Humana Inc. Aktie in der Gunst der Community: Nur Buy-Einschätzungen, keine Sell-Einschätzungen.
Das von der Community festgelegte Kursziel für Humana Inc. von 439 € impliziert eine deutliche Steigerung gegenüber dem aktuellen Kurs von 299.3 €.
